Antares Pharma (ATRS) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Antares Pharma Reports First Quarter 2015 Operating and Financial Results
May 11, 2015 7:00 AM EDTEWING, N.J., May 11, 2015 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (Nasdaq: ATRS) today reported operating and financial results for the first quarter ended March 31, 2015. The Company reported revenue of $8.3 million and net loss per share of $0.05. Antares ended the first quarter with $26.5 million in cash and investments and no debt.
Recent Developments and First Quarter 2015 Highlights
Priced a firm commitment underwritten public offering of 23,000,000 shares of the Company's common stock, which includes 3,000,000 shares pursuant to the underwriters' exercise of their option in full, at a purchase... MoreAntares Pharma Reports First Quarter 2015 Operating and Financial Results
May 11, 2015 7:00 AM EDTEWING, N.J., May 11, 2015 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (Nasdaq: ATRS) today reported operating and financial results for the first quarter ended March 31, 2015. The Company reported revenue of $8.3 million and net loss per share of $0.05. Antares ended the first quarter with $26.5 million in cash and investments and no debt.
Recent Developments and First Quarter 2015 Highlights
Priced a firm commitment underwritten public offering of 23,000,000 shares of the Company's common stock, which includes 3,000,000 shares pursuant to the underwriters' exercise of their option in full, at a purchase... More